Related Experiment Video
Updated: Feb 13, 2026

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele
Davina Gale1, Andrew R J Lawson1, Karen Howarth1
1Inivata Ltd, Granta Park, Cambridge, United Kingdom.
Introduction:
Detection and monitoring of circulating tumor DNA (ctDNA) is rapidly becoming a diagnostic, prognostic and predictive tool in cancer patient care. A growing number of gene targets have been identified as diagnostic or actionable, requiring the development of reliable technology that provides analysis of multiple genes in parallel. We have developed the InVision™ liquid biopsy platform which utilizes enhanced TAm-Seq™ (eTAm-Seq™) technology, an amplicon-based next generation sequencing method for the identification of clinically-relevant somatic alterations at low frequency in ctDNA across a panel of 35 cancer-related genes.
Materials And Methods:
We present analytical validation of the eTAm-Seq technology across two laboratories to determine the reproducibility of mutation identification. We assess the quantitative performance of eTAm-Seq technology for analysis of single nucleotide variants in clinically-relevant genes as compared to digital PCR (dPCR), using both established DNA standards and novel full-process control material.
Results:
The assay detected mutant alleles down to 0.02% AF, with high per-base specificity of 99.9997%. Across two laboratories, analysis of samples with optimal amount of DNA detected 94% mutations at 0.25%-0.33% allele fraction (AF), with 90% of mutations detected for samples with lower amounts of input DNA.
Conclusions:
These studies demonstrate that eTAm-Seq technology is a robust and reproducible technology for the identification and quantification of somatic mutations in circulating tumor DNA, and support its use in clinical applications for precision medicine.
Insights
The enhanced TAm-Seq (eTAm-Seq) technology reliably detects low-frequency mutations in circulating tumor DNA (ctDNA) for precision medicine. This amplicon-based sequencing method demonstrates high accuracy and reproducibility across multiple laboratories for cancer gene analysis.
Area of Science:
- Molecular Biology
- Genomics
- Oncology
Background:
- Circulating tumor DNA (ctDNA) is crucial for cancer diagnostics, prognostics, and predicting treatment response.
- Identifying multiple actionable gene targets in ctDNA requires advanced, parallel analysis technologies.
Purpose of the Study:
- To analytically validate the InVision™ platform utilizing enhanced TAm-Seq (eTAm-Seq) technology.
- To assess the reproducibility and quantitative performance of eTAm-Seq for somatic mutation detection in ctDNA.
Main Methods:
- Utilized eTAm-Seq, an amplicon-based next-generation sequencing method, to analyze a 35-gene panel.
- Conducted cross-laboratory validation and compared quantitative performance against digital PCR (dPCR) using DNA standards and controls.
Main Results:
- The assay detected mutant alleles down to 0.02% allele fraction (AF) with 99.9997% per-base specificity.
- Achieved 94% mutation detection at 0.25%-0.33% AF with optimal DNA input and 90% with lower input across two labs.
Conclusions:
- eTAm-Seq technology is robust and reproducible for identifying and quantifying somatic mutations in ctDNA.
- The validated technology supports clinical applications in precision oncology.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
10:41Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
Related Concept Videos
Multiple Allele Traits
Mutation, Gene Flow, and Genetic Drift
Cancers Originate from Somatic Mutations in a Single Cell
Mutations
Clinically Relevant Drug Product Specifications: Methods of Establishment
Overview of DNA Repair
Chemically...